#HimsAndHers #FDA #Peptides #HealthcareStocks #Telehealth #BiotechNews #PharmaTrends #WallStreet #HealthInnovation #StockMarketNews Read full article link in comment To view or add a comment, sign in - : The global GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period
Proinflammatory factors can impair tight junction protein expression
Stability and Handling# Dihexa is relatively stable due to its non-natural modifications (N-hexanoic acid cap, aminohexanoic amide C-terminus), which protect it from typical peptidase degradation
The weight loss industry is booming, with the global market for weight loss drugs expected to surpass $100 billion in the next few years, according to Morningstar Research Services LLC, a financial services firm in Chicago
In addition to cardiovascular outcomes, GLP-1 RAs have been studied in various fields, including endocrine disorders, renal diseases, and neurological conditions, generating encouraging findings in these areas
